A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Obstructive Sleep ApneaHypertension
Interventions
DRUG

Lorundrostat

Lorundrostat tablet.

DRUG

Placebo

Lorundrostat matching placebo tablet.

Trial Locations (27)

20854

Velocity Clinical Research, Rockville, Rockville

21045

Centennial Medical Group, Columbia

28037

Research Carolina Elite, Denver

30328

NeuroTrials Research Inc, Atlanta

31326

Centricity Research Rincon Pulmonology, Rincon

32117

Arrow Clinical Trials, Daytona Beach

32801

CNS Healthcare - Orlando (Clinical Neuroscience Solutions), Orlando

33176

PharmaDev Clinical Research Institute, LLC, Miami

33189

Nouvelle Clinical Research, Cutler Bay

35401

The University of Alabama, Tuscaloosa

38119

CNS Healthcare - Memphis (Clinical Neuroscience Solutions - Memphis), Memphis

45212

CTI Clinical Research Center, Cincinnati

48075

Revive Research Institute, Inc, Southfield

48377

Henry Ford Health System/Henry Ford Medical Center - Columbus, Novi

60634

Chicago Research Center Inc, Chicago

63042

Healthcare Research Network, Hazelwood

63123

Clayton Sleep Institute, St Louis

72211

Preferred Research Partners Inc., Little Rock

77340

Huntsville Research Institute LLC, Huntsville

78229

Sleep Therapy Research Center, San Antonio

85224

Chandler Clinical Trials, Chandler

92011

The Neurology Center of Southern California - Profound Research, LLC, Carlsbad

92501

Probe Clinical Research Corporation, Riverside

92801

Orange County Research Institute, Anaheim

97202

Northwest Research Center, Portland

98104

University of Washington, Seattle

07748

Patient First MD, Middletown

Sponsors
All Listed Sponsors
lead

Mineralys Therapeutics Inc.

INDUSTRY

NCT06785454 - A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension | Biotech Hunter | Biotech Hunter